Preparation and investigation of in vitro cytotoxic activity of pH-sensitive liposomes with sanguinarine Online publication date: Mon, 23-Sep-2019
by S.V. Lutsenko; O.I. Gudkova; V.V. Kashirin; T.I. Gromovykh; N.B. Feldman
International Journal of Nanotechnology (IJNT), Vol. 16, No. 1/2/3, 2019
Abstract: Sanguinarine is a benzophenanthridine alkaloid of plant origin showing antitumour, anti-inflammatory and a number of other activities. To increase the effectiveness of its therapeutic effect, sanguinarine was introduced into the pH-sensitive liposomes by the remote loading method using ammonium citrate. The average diameter of the obtained liposomes was equal to 144.8 ± 2.3 nm; zeta potential was equal to -16.3 ± 1.5 mV, the effectiveness of sanguinarine inclusion in liposomes was 68.7%. The release of sanguinarine from liposomes was prolonged; the lowest level of release was observed in a medium with a pH of 7.4, the highest at pH 5.5, which may be useful in preventing the release of the active substance in the blood stream and, conversely, in activating its release in the tumour growth zone. The cytotoxic activity of liposomal sanguinarine against cells of human squamous carcinoma A431 (IC50 9.5 μM) was significantly higher than its activity against the normal epidermal keratinocytes (NHEK) (IC50 25.1 μM). The drug also caused an effective dose-dependent induction of apoptosis in tumour cells of A431, while not affecting normal cells. Thus, liposomal sanguinarine can be considered as a promising antitumour agent acting on tumour cells by inducing apoptosis and exhibiting low cytotoxicity to normal human cells.
Online publication date: Mon, 23-Sep-2019
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Nanotechnology (IJNT):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email firstname.lastname@example.org